Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories

Summary

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. As HIT is considered a clinico-pathologic entity, laboratory practices have an important role in diagnosing or excluding HIT. It was the objective of this study to assess the current status of laboratory testing for HIT in North America. An online survey consisting of 67 questions related to laboratory testing for HIT was developed by the North American Specialized Coagulation Laboratory Association (NASCOLA), and distributed to its 59 members. The survey included queries about HIT test ordering practices, HIT immunoassay and activation assays performed, and reporting practices. Data was collected from the 44 NASCOLA laboratories who responded. Of these sites, 88% performed immunoassays for HIT, commonly using commercial assays. However, sites varied in practices related to use of controls, immunoglobulin class of antibody detected, and in result interpretation and reporting. Platelet activation assays for HIT were performed by 36% of sites, commonly using assays of serotonin release (50%) or heparin- induced platelet aggregation (43%). Sites varied in the use of washed platelets versus platelet-rich plasma, controls, and heparin concentrations. This survey is the first comprehensive assessment of patterns of practice in HIT testing among diagnostic coagulation laboratories in North America. We observed sitespecific variability of testing methods encompassing all stages of testing, including pre-analytical handling, testing methodologies, and result interpretation and reporting. The variability in HIT platelet activation assay methods among institutions indicates a need for proficiency testing to assess assay performance,and for consensus guidelines on HIT laboratory testing.

Keywords

Heparin-induced thrombocytopenia - laboratory diagnosis - platelet-factor 4 - thrombocytopenia

• References

• 1 Arepally GM, Ortel TL. Clinical practice. Heparininduced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
• 2 Greinacher A, Eichler P, Lietz T. et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106: 2921-2922.
• 3 Warkentin TE, Levine MN, Hirsh J. et al. Heparininduced thrombocytopenia in patients treated with lowmolecular- weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 4 Warkentin TE, Roberts RS, Hirsh J. et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-2524.
• 5 Warkentin TE, Chong BH, Greinacher A. Heparininduced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
• 6 Greinacher A, Farner B, Kroll H. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
• 7 Fontana P, Bodmer A, Gruel Y. et al. Skin necrosis is a clinical manifestation of low-molecular weight heparin- induced thrombocytopenia. Thromb Haemost 2004; 91: 196-197.
• 8 Lubenow N, Kempf R, Eichner A. et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 37-42.
• 9 Rice L, Attisha WK, Drexler A. et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136: 210-215.
• 10 Smythe MA, Stephens JL, Mattson JC. Delayedonset heparin-induced thrombocytopenia. Ann Emerg Med 2005; 45: 417-419.
• 11 Warkentin TE, Kelton JG. Delayed-onset heparininduced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
• 12 Visentin GP, Ford SE, Scott JP. et al. Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
• 13 Kelton JG, Smith JW, Warkentin TE. et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
• 14 Rauova L, Zhai L, Kowalska MA. et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107: 2346-2353.
• 15 Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127 (Suppl. 02) 35S-45S.
• 16 Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 311S-37S.
• 17 Pouplard C, Amiral J, Borg JY. et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-706.
• 18 Verma AK, Levine M, Shalansky SJ. et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23: 745-753.
• 19 Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006; 20: 259-272.
• 20 Institute GT. PF4 Enhanced. 2005. Available from: http://www.gtidiagnostics.com/documentation/coagxhat13&45_di_eng_011305.pdf
• 21 Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti- PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 281-282.
• 22 Refaai MA, Van Cott EM, Laposata M. The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol 2003; 119: 497-504.
• 23 Amiral J, Wolf M, Fischer A. et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-959.
• 24 Amiral J, Bridey F, Wolf M. et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73: 21-28.
• 25 Lindhoff-Last E, Eichler P, Stein M. et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000; 97: 387-393.
• 26 Suh JS, Malik MI, Aster RH. et al. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997; 54: 196-201.
• 27 Warkentin TE, Sheppard JA, Moore JC. et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146: 341-346.
• 28 Juhl D, Eichler P, Lubenow N. et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
• 29 Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006; 81: 36-44.
• 30 Zwicker JI, Uhl L, Huang WY. et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133-2137.
• 31 Fabris F, Luzzatto G, Soini B. et al. Risk factors for thrombosis in patients with immune mediated heparininduced thrombocytopenia. J Intern Med 2002; 252: 149-154.
• 32 Warkentin TE, Hayward CP, Smith CA. et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371-379.
• 33 Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004; 30: 359-368.
• 34 Francis JL. Detection and significance of heparinplatelet factor 4 antibodies. Semin Hematol 2005; 42 3 Suppl 3 S9-14.